CEO and managing director Dr Paul McKenzie said, “CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in our core Ig franchise. We continue to advance key initiatives to improve gross margin, which is tracking according to our plans." …
Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus
February 11, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
The Dispatched Podcast - 6 June
June 6, 2025 - - Podcast -
Health department amends published blood review information
June 5, 2025 - - Latest News -
'My experience was awful, I really had to fight to be taken seriously and advocate for myself'
June 5, 2025 - - Latest News -
UK moves to pricing changes as Australian-based companies baulk at listings
June 5, 2025 - - Latest News -
Clarity announces positive top-line results from DISCO trial
June 5, 2025 - - Australian Biotech -
Clinical trial success kicks off $5m fund-raising round for WA’s Lixa
June 5, 2025 - - Australian Biotech -
Wesfarmers Health acquires Pharmacy 4 Less group
June 4, 2025 - - Latest News